-transparent.png){kind=logo}
Tumor cells suspensions prepared from 129 B- or non-T cell malignancies were investigated with a panel of 10 monoclonal antibodies and conventional surface marker techniques. Surface immunoglobulin (sIg) and B1 antigen proved to be the most useful markers for B-cell lineage. Six major subtypes of acute lymphoblastic leukemia (ALL) of non-T cell nature are now recognized by these immunological techniques, including null-ALL, Ia-ALL, lymphoid stem cell ALL, pre-pre-B ALL, pre-B ALL and B-ALL. In cases of chronic leukemias and lymphomas of non-T cell nature, 80% of the tumor was defined by sIg and 88% by B1 antigen as definitely of B-cell lineage. The clonal character was also defined in 68% of the tumor on the basis of the detection of predominant single light chain in sIg. Ia-like antigen was detected in almost all cases (96%). Leukemic cells from all cases of chronic lymphocytic leukemia (CLL), chronic lymphosarcoma cell leukemia (CLsCL) and hairy cell leukemia (HCL) reacted with OKIa1 and anti-B1, and leukemic cells from most of them with anti-pan T monoclonal antibody (10.2). In more than half of CLL and CLsCL, leukemic cells were reactive with J5, OKM1, 9.6 and OKT8, but not with OKT3, OKT4 and OKT6. HCL cells had almost the same reactivity with these monoclonal antibodies as CLL and CLsCL cells except that J5 remained unreactive. These results indicated that Japanese CLL, CLsCL and HCL were different from Western ones at least with respect to surface marker characteristics. In cases of lymphomas, heavy chains of sIg were expressed in polyclonal fashion, especially in follicular lymphoma and diffuse lymphomas of medium sized cell type and large cell type, indicating that lymphomas of these types may originate from follicular center cells of the heavy chain switching stage. Anti-T monoclonals were also reactive with lymphoma cells. In about half of follicular lymphomas and diffuse lymphomas of the medium sized cell type, lymphoma cells reacted with 10.2, and less frequently with 9.6, OKT4 and OKT3. On the other hand, only in one or two cases of diffuse lymphoma of the large cell type and of immunoblastic sarcoma (IBS), did tumor cells react with 10.2 and 9.6, but this was exceptional. In more than 25% of IBS, tumor cells also reacted with OKT8, but not with OKT4 and OKT3. These results indicated that anti-T monoclonals are no longer specific for T-cell lineage.(ABSTRACT TRUNCATED AT 400 WORDS)
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
April 2006,
Seminars in oncology,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
June 2010,
Leukemia & lymphoma,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
May 1983,
Blood,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
October 1983,
Blood,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
January 1989,
British journal of haematology,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
September 1986,
Blood,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
August 2008,
The New England journal of medicine,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
January 1981,
International journal of immunopharmacology,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
January 2019,
Human vaccines & immunotherapeutics,
M Shimoyama, and
K Minato, and
K Tobinai, and
M Nagai, and
M Hirose
November 1989,
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
